Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects
Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
This single-center, randomized, placebo-controlled, double-blind, dose-increasing study was
designed to evaluate the safety, tolerability, and pharmacokinetics of multiple successive
dosing in healthy Chinese adult subjects.In this study, 20 healthy adult subjects were
enrolled in a multi-dose study in the 30mg and 40mg groups.